Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

158.74 +0.26 (+0.16%)
Streaming Delayed Price Updated: 2:23 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,415,024
Open 158.37
Bid (Size) 158.73 (2)
Ask (Size) 158.74 (1)
Prev. Close 158.48
Today's Range 157.84 - 159.31
52wk Range 143.13 - 175.39
Shares Outstanding 2,628,679,824
Dividend Yield 3.00%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Johnson & Johnson Nears Approval for $6.5B Long Standing Talc Settlement
Johnson & Johnson seeks to resolve thousands of lawsuits through bankruptcy proceedings, facing both legal challenges and critical milestones. 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
Via Benzinga

Performance

YTD
-0.77%
-0.77%
1 Month
+6.36%
+6.36%
3 Month
+3.97%
+3.97%
6 Month
+1.92%
+1.92%
1 Year
-8.21%
-8.21%

More News

Read More
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Via Benzinga
Topics Economy
Exposures Interest Rates
CrowdStrike: What's Ahead For Cybersecurity Player In The Wake Of Its Corporate Crisis
Via Investor's Business Daily
Nvidia Looks To Disrupt The Health Care Industry With AI
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Exploring NYSE:JNJ's dividend characteristics.
Via Chartmill
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
Via InvestorPlace
7 Dependable Dividend Stocks for Long-Term Income
Via InvestorPlace
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
Via Benzinga
Exposures COVID-19
J&J Moves Closer to Resolving Baby Powder Lawsuits, 75% of Plaintiffs Support $6.5B Settlement
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 Blue-Chip Stocks to Buy on the Dip: August 2024
Via InvestorPlace
Medicare Costs For Johnson & Johnson's Psoriasis Drug Stelara Double When Obtained at Pharmacies
Via Benzinga
2 Healthcare Stocks to Buy Hand Over Fist in August
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Nasdaq Sell-Off: 5 Unstoppable Stocks to Buy That Can Protect Your Principal and Grow Your Wealth in an Unpredictable Market
Via The Motley Fool
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
The 3 Best Dividend Aristocrats to Buy for Sustainable Income: August 2024
Via InvestorPlace
3 Dividend Growth Stocks to Buy Hand Over Fist in August
Via The Motley Fool
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Via FinancialNewsMedia
3 Dividend Growth Stocks to Accumulate on Dips: August Edition
Via InvestorPlace
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
The Market's Excessive Recession Fears
Via Talk Markets
Topics Economy
Exposures Economy
Large Cap Biopharma And Healthcare, A Port In A Storm
Via Talk Markets
3 Defensive Stocks Weathering the Market Storm
Via MarketBeat
Topics Economy Stocks
Exposures Economy US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.